AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
These drugs are sometimes used on their own or in combination with other treatments ... Eucrisa is approved for people 3 months and older, while Zoryve is approved for people 6 years of age and older.
Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...
Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 ... pointing to a durable effect for a drug that could provide an alternative to injectables.
That means it could be dosed without considering meal timings, which is a consideration with some drugs in the oral GLP-1 class. For example, Novo Nordisk's oral formulation of semaglutide for dia ...